Bausch Health Companies (BHC) vs Nurix Therapeutics (NRIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nurix Therapeutics (NRIX) has outperformed Bausch Health Companies (BHC) over the past year, gaining 131.2% versus a loss of 3.8%. Over five years, NRIX leads with a -21.2% price change compared with -78.4% for BHC. Nurix Therapeutics is the larger company by market cap ($2.36 billion vs $2.30 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | NRIX |
|---|---|---|
| Share price | $6.15 | $22.73 |
| Market cap | $2.30B | $2.36B |
| 1-day change | +2.16% | +0.58% |
| YTD return | -11.51% | +19.82% |
| 1-year return | -3.76% | +131.23% |
| 5-year return | -78.41% | -21.16% |
| Forward P/E | 1.47 | — |
| EPS (TTM) | $-3.01 | $-3.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.00 | $28.23 |
| 52-week low | $4.33 | $9.00 |
| Distance from 52-week high | -23.12% | -19.48% |
| Analyst consensus | hold | none |
| Avg. price target upside | +21.95% | +49.27% |
| Average volume | 3.26M | 1.27M |
| Shares outstanding | 373.99M | 103.78M |
| Employees | 20,300 | 317 |
| Sector | Healthcare | Health Care |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRIX has outperformed BHC by 135.0 percentage points over the past year.
- The two companies sit in different sectors: Bausch Health Companies in Healthcare and Nurix Therapeutics in Health Care.
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Healthcare · Drug Manufacturers - Specialty & Generic · 20,300 employees
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
BHC vs NRIX FAQ
Which is bigger, Bausch Health Companies or Nurix Therapeutics?
Nurix Therapeutics (NRIX) is larger, with a market capitalization of $2.36B compared with $2.30B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, BHC or NRIX?
NRIX returned +131.23% over the past 12 months, compared with -3.76% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Nurix Therapeutics in the same industry?
No. Bausch Health Companies is in the Healthcare sector, while Nurix Therapeutics is in Health Care.